| Schwartzentruber et al. Nature 2012; Mackay et al. Cancer Cell 2017 (HERBY) agent:phgg-research-bot-2026-05-09 vs_014d671da8fab1b7 | paper | missing | missing | 1 |
| Real-world compassionate use data, Gustave Roussy, 2024 reviewer:will-blair vs_01ed2dd05fbeac94external | paper | missing | missing | 1 |
| Lin et al. Cancer Cell 2018; ICR/CCR pediatric HGG immune profiling agent:phgg-research-bot-2026-05-09 vs_04bc2b7cdd7d2470 | paper | missing | missing | 1 |
| Persson et al. 2022 (Neuro-oncology); Khairkhah et al. 2026 (Neoplasia) reviewer:will-blair vs_061cddf1be44de97external | paper | 2022 | missing | 1 |
| Fangusaro et al. Lancet Oncol 2019 (selumetinib NF1-LGG); Helfferich et al. Pediatr Drugs 2016 agent:phgg-research-bot-2026-05-09 vs_067281016d0b1551 | paper | missing | missing | 1 |
| Diffuse midline glioma H3K27M multi-cohort analysis reviewer:will-blair vs_07f89d03f9759372 | paper | 2022 | missing | 1 |
| Chavaz et al. 2026 (Neuro-oncology meta-analysis, n=164 infant-type HGG) reviewer:will-blair vs_098727d593935a54external | paper | 2026 | missing | 1 |
| Age-dependent CYP3A4 ontogeny physiologically based pharmacokinetic modeling reviewer:will-blair vs_104bf735f93e5b79 | paper | 2024 | missing | 1 |
| Calaminus et al. Lancet Oncol 2013; Bartels et al. Pediatr Blood Cancer 2020 agent:phgg-research-bot-2026-05-09 vs_13669ff10874447f | paper | missing | missing | 1 |
| Carvalho et al. 2019 Communications Biology reviewer:will-blair vs_150c1fec7f38f4a5external | paper | 2019 | missing | 1 |
| Mechanistic studies in endometrial and CLL models; pharmacological profiling reviewer:will-blair vs_15dbfd6e0032d1c0external | paper | missing | missing | 1 |
| Karim et al. 2025 (Frontiers Oncology, n=130 Egyptian cohort) reviewer:will-blair vs_161fd0899774d830external | paper | 2025 | missing | 1 |
| Zhukova et al. J Clin Oncol 2013; Waszak et al. Nature 2018 (germline TP53) agent:phgg-research-bot-2026-05-09 vs_169e023b6b2e5425 | paper | missing | missing | 1 |
| BIOMEDE phase 2 international trial, Nature Medicine reviewer:will-blair vs_1a5f91868ccc2009 | paper | 2026 | missing | 1 |
| EZHIP inhibits PRC2 activity through H3K27M-like mechanism (Nature Communications, s41467-019-09981-6) reviewer:will-blair vs_1fc2f41487432632 | paper | 2019 | missing | 1 |
| JCO integrated efficacy analysis; FDA accelerated approval dossier, 2025 reviewer:will-blair vs_24d093290a28ddd3external | paper | missing | missing | 1 |
| Geyer et al. J Clin Oncol 2005 (Baby POG); Cohen et al. Cancer 2015 (infant medulloblastoma) agent:phgg-research-bot-2026-05-09 vs_26513dc3497e9df6 | paper | missing | missing | 1 |
| Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults 2021 (10.1093/noajnl/vdab061); P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion 2023 (10.1186/s40478-023-01573-2) reviewer:will-blair vs_282defff6caff631 | paper | 2023 | missing | 1 |
| Mulhern et al. J Clin Oncol 2005; Merchant et al. Cancer 2009 (proton outcomes) agent:phgg-research-bot-2026-05-09 vs_29ed57bf3b927139 | paper | missing | missing | 1 |
| Buczkowicz et al. 2014 Nature Genetics; Mackay et al. 2016 Nature Communications reviewer:will-blair vs_2d9590fda9f06305external | paper | 2016 | missing | 1 |
| A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered (Acta Neuropathologica) reviewer:will-blair vs_2e6ba54261b26552 | paper | 2023 | missing | 1 |
| H3K27M induces defective chromatin spread of PRC2 (Nature Communications, s41467-019-09140-x) reviewer:will-blair vs_2f0309860c6b2d74 | paper | 2019 | missing | 1 |
| Metabolic dependencies and neural progenitor dysregulation: driving forces in paediatric high-grade glioma development 2026 (10.1007/s10555-026-10325-2) reviewer:will-blair vs_2ff0a96c5a0e319b | paper | 2026 | missing | 1 |
| Liu et al. 2025 (Neuro-oncology Advances, n=95 adult recurrent HGG) reviewer:will-blair vs_30218e2dfb2be270external | paper | 2025 | missing | 1 |
| Mackay et al. Cancer Cell 2017; Sturm et al. Cancer Cell 2012 agent:phgg-research-bot-2026-05-09 vs_3378ff0a8c212955 | paper | missing | missing | 1 |
| Eytan et al. 2022 (Frontiers Oncology) reviewer:will-blair vs_345a5c9d2e42be3eexternal | paper | 2022 | missing | 1 |
| Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors 2022 (10.1093/noajnl/vdac133); Nakatogawa et al. 2025 (10.1186/s40478-025-01989-y) reviewer:will-blair vs_385cf697d74601b8 | paper | 2025 | missing | 1 |
| Buczkowicz et al. Nat Genet 2014; Wu et al. Nat Genet 2014 agent:phgg-research-bot-2026-05-09 vs_3911af7c1df96a9e | paper | missing | missing | 1 |
| An oncohistone-driven H3.3K27M/CREB5/ID1 axis maintains stemness (Nature Communications, s41467-025-58795-2) reviewer:will-blair vs_3a7dc13a33032814 | paper | 2025 | missing | 1 |
| Royston et al. 2026 (10.1111/jcmm.71092) reviewer:will-blair vs_3d060301bb87104e | paper | 2026 | missing | 1 |
| Hargrave et al. Lancet Oncol 2023; Bouffet et al. NEJM 2023 (FIREFLY-2) agent:phgg-research-bot-2026-05-09 vs_3e5daa3d1817889c | paper | missing | missing | 1 |
| Integrated genomic studies (Buczkowicz et al., Castel et al., recent structural variant analyses) reviewer:will-blair vs_410aeadd993b773eexternal | paper | 2022 | missing | 1 |
| Pachocki & Hol 2022 (Journal of Neuroinflammation); Chavaz et al. 2026 reviewer:will-blair vs_418035ebab1c6cc9external | paper | 2022 | missing | 1 |
| COG ACNS0126 phase II trial reviewer:will-blair vs_47f0d630afe8e716 | paper | 2011 | missing | 1 |
| Besson et al. 2024 eLife reviewer:will-blair vs_4b621ca3a5611d65external | paper | 2024 | missing | 1 |
| G207 phase I pediatric high-grade glioma trial, New England Journal of Medicine reviewer:will-blair vs_4ba55a2840324e28 | paper | 2021 | missing | 1 |
| Nakatogawa et al. 2025 (10.1186/s40478-025-01989-y); cIMPACT-NOW update 6 2020 (10.1111/bpa.12832) reviewer:will-blair vs_4cc7639178b5f79f | paper | 2025 | missing | 1 |
| Williams et al. 2023 (10.1007/s00401-023-02609-6); Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults 2021 (10.1093/noajnl/vdab061) reviewer:will-blair vs_51e8862409569be0 | paper | 2023 | missing | 1 |
| ONC201 clinical efficacy in H3K27M-mutant gliomas (Cancer Discovery) reviewer:will-blair vs_548c1751a8b99905 | paper | 2021 | missing | 1 |
| BIOMEDE trial exome sequencing and molecular architecture reviewer:will-blair vs_56e174a066e49cb8 | paper | 2021 | missing | 1 |
| v0.301 pediatric HGG external-review depth wave reviewer:v0.301-depth vs_570e1f9185078850 | paper | missing | missing | 2 |
| Okubo et al. 2026 (10.1016/j.bbrc.2026.153471); Generation and multi-dimensional profiling of a childhood cancer cell line atlas 2023 (10.1016/j.ccell.2023.03.007) reviewer:will-blair vs_5732427ba1e71411 | paper | 2026 | missing | 1 |
| Hoffman et al. Lancet Oncol 2018; Cooney et al. Cancer 2020 agent:phgg-research-bot-2026-05-09 vs_5ba408f2955ac718 | paper | missing | missing | 1 |
| H3.3-K27M drives neural stem cell-specific gliomagenesis (Cancer Cell, S1535-6108(21)00049-0) reviewer:will-blair vs_5c40cce1c66bfb6a | paper | 2021 | missing | 1 |
| Northcott et al. Nature 2017 (Cavalli et al. subgroups); Roussel and Robinson, Cold Spring Harb Perspect Biol 2013 agent:phgg-research-bot-2026-05-09 vs_5d7a879ffce5cc31 | paper | missing | missing | 1 |
| Revisiting pediatric HGGs and PNETs according to the WHO CNS5 criteria 2025 (10.1093/noajnl/vdaf175) reviewer:will-blair vs_5f40a6bba4ce9327 | paper | 2025 | missing | 1 |
| Pajtler et al. Cancer Cell 2015; Tauziede-Espariat et al. Acta Neuropathol 2024 agent:phgg-research-bot-2026-05-09 vs_5fceac6c90cbecd1 | paper | missing | missing | 1 |
| Chavaz et al. 2026 (Neuro-oncology meta-analysis, n=164) reviewer:will-blair vs_61e4aab48c99a217external | paper | 2026 | missing | 1 |
| Monje et al. 2011 PNAS; Foreman et al. 2020+ developmental timing literature reviewer:will-blair vs_6503cf26ad48017bexternal | paper | 2011 | missing | 1 |
| European Journal of Cancer compassionate use program (Gustave Roussy), 2024 reviewer:will-blair vs_673d69ca36a6c261external | paper | missing | missing | 1 |
| Exploring the tumor microenvironment in DIPG (PMC12164617) reviewer:will-blair vs_6b661a0c55bf0f4a | paper | 2024 | missing | 1 |
| DMG patient-derived culture m6A profiling and FTO inhibitor studies, 2026 reviewer:will-blair vs_6c2e70d5b46df60dexternal | paper | missing | missing | 1 |
| Modern radiotherapy pediatric brain tumor late effects systematic review reviewer:will-blair vs_71cc4689dffee5b8 | paper | 2023 | missing | 1 |
| Cavalli et al. Cancer Cell 2017; Ramaswamy et al. Acta Neuropathol 2016 agent:phgg-research-bot-2026-05-09 vs_7357be142b588d3b | paper | missing | missing | 1 |
| Cohen et al. Pediatr Blood Cancer 2017; ACNS0126 follow-up; review: Hennika et al. Front Oncol 2017 agent:phgg-research-bot-2026-05-09 vs_74ea18467bd85e4c | paper | missing | missing | 1 |
| Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens 2024 (10.1093/neuonc/noae228) reviewer:will-blair vs_75a58afa7e022874 | paper | 2024 | missing | 1 |
| Majzner et al. 2022 Nature reviewer:will-blair vs_7c5038ffa861a48dexternal | paper | 2022 | missing | 1 |
| GD2-CAR T cell therapy for H3K27M-mutated gliomas (Nature, s41586-022-04489-4) reviewer:will-blair vs_7d2942ba6e79cdad | paper | 2022 | missing | 1 |
| Campbell et al. Cell 2017 (pediatric pan-cancer TMB); Bouffet et al. J Clin Oncol 2016 (CMMRD case) agent:phgg-research-bot-2026-05-09 vs_7f70fa23926a81c1 | paper | missing | missing | 1 |
| Neuro-oncology mechanistic review and ClpP activation studies, 2023-2024 reviewer:will-blair vs_81559aa2458c0d83external | paper | missing | missing | 1 |
| Subbiah et al. Cancer Discov 2019 (FGFR fusions); pediatric LGG NCI MATCH cohort agent:phgg-research-bot-2026-05-09 vs_824ad05a2881e9c6 | paper | missing | missing | 1 |
| H3K27M mutant glioma: Disease definition and biological underpinnings (Neuro-Oncology, S92/7306459) reviewer:will-blair vs_82f5e05c9e1359d1 | paper | 2024 | missing | 1 |
| Brastianos et al. NEJM 2023 (papillary craniopharyngioma BRAF V600E); Apps et al. Pituitary 2018 agent:phgg-research-bot-2026-05-09 vs_836368bd9f1a9327 | paper | missing | missing | 1 |
| Real-world multi-center Hong Kong retrospective study; n=27 adult Chinese patients reviewer:will-blair vs_84bfcfc300364208external | paper | missing | missing | 1 |
| Okubo et al. 2026 (10.1016/j.bbrc.2026.153471); H3F3A-G34R mutant high grade neuroepithelial neoplasms 2019 (10.1186/s40478-019-0731-5) reviewer:will-blair vs_8558d19a82640f3c | paper | 2026 | missing | 1 |
| Valentini et al. 2025 (Clinical Oncology, HIT-HGG/HIT-GBM cohort n=19) reviewer:will-blair vs_8673d1935602016aexternal | paper | 2025 | missing | 1 |
| Valvi et al. 2025 (Frontiers Molecular Neuroscience review) reviewer:will-blair vs_88217e1af5f1d74cexternal | paper | 2025 | missing | 1 |
| Nagaraja et al. 2017; Madhusoodanan et al. 2020 Cell Death & Disease reviewer:will-blair vs_8871c659ca3e890dexternal | paper | 2020 | missing | 1 |
| Wrede et al. Cancer 2009 (CPC outcomes); Mistry et al. Pediatr Blood Cancer 2018 agent:phgg-research-bot-2026-05-09 vs_8aaf77185088e702 | paper | missing | missing | 1 |
| Neuro-oncology mechanism review; pre-clinical in vitro assays reviewer:will-blair vs_902a7eb4261f7d34external | paper | missing | missing | 1 |
| Arrillaga-Romany et al. Neuro-Oncology 2024 (ONC201 phase 2); ACTION trial NCT05580562 agent:phgg-research-bot-2026-05-09 vs_91d81b9fe3a5c8f0 | paper | missing | missing | 1 |
| Pooled safety analysis across five clinical trials; compassionate use programs reviewer:will-blair vs_95868c02be5b0684external | paper | missing | missing | 1 |
| H3-K27M-Mutant Nucleosomes Interact with MLL1 to Shape the Glioma Epigenetic Landscape (bioRxiv, 2021.08.09.455680) reviewer:will-blair vs_975d6bcb7d97d49d | paper | 2021 | missing | 1 |
| Hayashi et al. 2019 Nature Communications reviewer:will-blair vs_9a4b2eb0e8d97912external | paper | 2019 | missing | 2 |
| Tian et al. 2025 (10.1002/pdi3.70027); Single-Cell Profiling of Pediatric High-Grade Gliomas reviewer:will-blair vs_9b05eaf26e3faeca | paper | 2025 | missing | 1 |
| Pajtler et al. Cancer Cell 2015; Pajtler et al. Acta Neuropathol 2018 agent:phgg-research-bot-2026-05-09 vs_9b7724f9cc8896a8 | paper | missing | missing | 1 |
| PBTC-022 efficacy study reviewer:will-blair vs_9c0360e60b5047ec | paper | 2010 | missing | 1 |
| Bayliss et al. Sci Transl Med 2016; Pajtler et al. Acta Neuropathol 2018 agent:phgg-research-bot-2026-05-09 vs_9dbe530b08f1809a | paper | missing | missing | 1 |
| Reulen et al. JAMA 2011 (BCCSS); Bowers et al. J Clin Oncol 2017 agent:phgg-research-bot-2026-05-09 vs_a23c4725d31c6962 | paper | missing | missing | 1 |
| Rojas-Charry et al. 2023 Nature Communications reviewer:will-blair vs_a3b59e1bcf3c6701external | paper | 2023 | missing | 1 |
| Louveau et al. 2018; Majzner et al. 2022 reviewer:will-blair vs_a55279c25f5c84bcexternal | paper | 2022 | missing | 1 |
| H3 K27M-altered glioma treatment landscape (Neuro-Oncology, S110/7475775) reviewer:will-blair vs_a676a201a87f6724 | paper | 2024 | missing | 1 |
| Velammal et al. 2025 (Child's Nervous System systematic review, n=40 pediatric patients) reviewer:will-blair vs_a8a3b3dc0a24b41bexternal | paper | 2025 | missing | 1 |
| Therapeutically targeting the unique disease landscape of pediatric high-grade gliomas 2024 (10.3389/fonc.2024.1347694); A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon 2025 (10.1038/s41698-025-01070-w) reviewer:will-blair vs_abac320e4b30b6c6 | paper | 2024 | missing | 1 |
| FDA accelerated approval, August 2025; Jazz Pharmaceuticals regulatory announcement reviewer:will-blair vs_ae1d889e422fb9b7external | paper | missing | missing | 1 |
| Pediatric DMG molecular subtyping and BRAF-targeted therapy response reviewer:will-blair vs_ae2a77028f921016 | paper | 2023 | missing | 1 |
| Targeting DNA Repair and Survival Signaling in DIPG (PMC10762335) reviewer:will-blair vs_af158c6b2b6c8d94 | paper | 2024 | missing | 1 |
| Revisiting pediatric HGGs and PNETs according to the WHO CNS5 criteria 2025 (10.1093/noajnl/vdaf175); Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO Classification 2022 (10.32074/1591-951x-830) reviewer:will-blair vs_b59af407291c9215 | paper | 2025 | missing | 1 |
| Johann et al. Cancer Cell 2016 (ATRT molecular subgroups); Reddy et al. Pediatr Blood Cancer 2020 (treatment outcomes) agent:phgg-research-bot-2026-05-09 vs_b8cf8c159d47074c | paper | missing | missing | 1 |
| CONNECT TarGeT-D olutasidenib phase 2 pediatric HGG trial reviewer:will-blair vs_be121dff87a8ab1a | paper | 2024 | missing | 1 |
| Roujeau et al. J Neurooncol 2007; Williams et al. Neurosurgery 2020 (modern series) agent:phgg-research-bot-2026-05-09 vs_bee93ac716a2e1fb | paper | missing | missing | 1 |
| Sex-specific differences pediatric/adult glioblastoma methylome-transcriptome analysis reviewer:will-blair vs_bfd192b993ac0751 | paper | 2021 | missing | 1 |
| Puigdelloses Vallcorba et al. 2025 (Journal of Clinical Investigation) reviewer:will-blair vs_ca13387b5631f75eexternal | paper | 2025 | missing | 1 |
| Oncogenic Mechanisms of Histone H3 Mutations 2016 (10.1101/cshperspect.a026443); H3K36 trimethylation-mediated biological functions in cancer 2021 (10.1186/s13148-021-01187-2) reviewer:will-blair vs_ce264e4fee4b4f7c | paper | 2017 | missing | 1 |
| COG ACNS0423 phase II trial reviewer:will-blair vs_d12f6af2146b9b97 | paper | 2016 | missing | 1 |
| Khairkhah et al. 2026 (Neoplasia immunopeptidomics study) reviewer:will-blair vs_d7792fa27c780bd9external | paper | 2026 | missing | 1 |
| MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant DMG (Frontiers Oncology) reviewer:will-blair vs_d888fbb717a320da | paper | 2019 | missing | 1 |
| Pediatric HGG drug efflux transporter immunohistochemical and functional analysis reviewer:will-blair vs_dc1f3992e2baaf0e | paper | 2013 | missing | 1 |
| PRC2 structural and mechanistic studies; H3K27M epigenetic profiling reviewer:will-blair vs_ddb455de384593c1external | paper | missing | missing | 1 |
| Madhusoodanan et al. 2020 Cell Death & Disease reviewer:will-blair vs_e004f05385a3d4ceexternal | paper | 2020 | missing | 1 |
| Johann et al. Cancer Cell 2016; Reddy et al. Pediatr Blood Cancer 2020 agent:phgg-research-bot-2026-05-09 vs_e0ba353d6fde2658 | paper | missing | missing | 1 |
| PNOC published trials; CBTN annual reports; review: Bornhorst et al. Pediatr Blood Cancer 2022 agent:phgg-research-bot-2026-05-09 vs_e1958158f378896d | paper | missing | missing | 1 |
| Buell et al. 2021 Acta Neuropathologica Communications reviewer:will-blair vs_e3e1dbbe670fc6b5external | paper | 2021 | missing | 1 |
| Nakatogawa et al. 2025 (10.1186/s40478-025-01989-y); Imaging features associated with H3 K27-altered and H3 G34-mutant gliomas: a narrative systematic review 2022 (10.1186/s40644-022-00500-3) reviewer:will-blair vs_e44d496725f50254 | paper | 2025 | missing | 1 |
| Brown et al. J Clin Oncol 2020 (CC001); Kazda et al. Strahlenther Onkol 2014 agent:phgg-research-bot-2026-05-09 vs_e4da137edbc045a6 | paper | missing | missing | 1 |
| ONC201 phase I dose escalation/expansion pediatric DMG trial, Neuro-Oncology reviewer:will-blair vs_e69aeb00b1b9ef83 | paper | 2022 | missing | 1 |
| Real-world Japanese C-CAT database analysis; n=114 diffuse midline glioma patients reviewer:will-blair vs_e6fd7fc5dafe75d5external | paper | missing | missing | 1 |
| Cellular Reprogramming of H3K27M pediatric glioma to neuron-like state (Acta Neuropathologica Communications) reviewer:will-blair vs_e8626be83ffe69c9 | paper | 2025 | missing | 1 |
| Hashizume et al. Nat Med 2014; review: Vitanza et al. Curr Treat Options Oncol 2019 agent:phgg-research-bot-2026-05-09 vs_e920e5a3f2e4a545 | paper | missing | missing | 1 |
| Persson et al. 2022 (Neuro-oncology); Jackson et al. 2023 (Neuro-oncology) reviewer:will-blair vs_ed9ee77b18841703external | paper | 2023 | missing | 1 |
| Schmiegelow et al. Eur J Cancer 2003; Patterson et al. Pediatr Blood Cancer 2017 agent:phgg-research-bot-2026-05-09 vs_eedf846948355b55 | paper | missing | missing | 1 |
| West China Hospital comparative cohort analysis, 2016-2021; n=105 (51 adults, 54 children) reviewer:will-blair vs_f435e6ea78f4042eexternal | paper | missing | missing | 1 |
| Pediatric Diffuse Midline Glioma H3K27-Altered (PMC11120159) reviewer:will-blair vs_f982c1eecb59e377 | paper | 2024 | missing | 1 |